Donald J L Jones

List of Publications by Year
in descending order

72 papers	3,270 citations	236925 25 h-index	149698 56 g-index
72 all docs	72 docs citations	72 times ranked	5166 citing authors

#	Article	IF	Citations
1	Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. Cancer Research, 2010, 70, 7392-7399.	0.9	511
2	Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. British Journal of Cancer, 2004, 90, 1011-1015.	6.4	387
3	Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4â€²-tetramethoxystilbene. British Journal of Cancer, 2004, 90, 736-744.	6.4	231
4	Trimethylamine *N*-oxide and prognosis in acute heart failure. Heart, 2016, 102, 841-848.	2.9	195
5	Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 105-11.	2.5	194
6	Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 120-5.	2.5	173
7	Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction. Clinical Chemistry, 2017, 63, 420-428.	3.2	120
8	DNA adducts: Mass spectrometry methods and future prospects. Toxicology and Applied Pharmacology, 2005, 207, 293-301.	2.8	99
9	Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administrationâ€"A Clinical Pilot Study Including Assessment of Patient Acceptability. Cancer Prevention Research, 2013, 6, 119-128.	1.5	89
10	The Human Apoptosis-inducing Protein AMID Is an Oxidoreductase with a Modified Flavin Cofactor and DNA Binding Activity. Journal of Biological Chemistry, 2005, 280, 30735-30740.	3.4	82
11	Curcumin ameliorates oxaliplatinâ€induced chemoresistance in HCT116 colorectal cancer cells *in vitro* and *in vivo*. International Journal of Cancer, 2011, 129, 476-486.	5.1	77
12	Vitamin D and prognosis in acute myocardial infarction. International Journal of Cardiology, 2013, 168, 2341-2346.	1.7	70
13	Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886.	7.1	68
14	Proenkephalin, Renal Dysfunction, andÂPrognosis in Patients With AcuteÂHeartÂFailure. Journal of the American College of Cardiology, 2017, 69, 56-69.	2.8	66
15	Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma. PLoS ONE, 2012, 7, e51119.	2.5	62
16	Proenkephalin and Prognosis After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 280-289.	2.8	56
17	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
18	Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. British Journal of Cancer, 2004, 91, 1213-1219.	6.4	40

#	Article	IF	Citations
19	Determination of Endogenous and Exogenously Derived N7-(2-Hydroxyethyl)guanine Adducts in Ethylene Oxide-Treated Rats. Chemical Research in Toxicology, 2007, 20, 290-299.	3.3	35
20	Dose-Response Relationships for N7-(2-Hydroxyethyl)Guanine Induced by Low-Dose [14C]Ethylene Oxide: Evidence for a Novel Mechanism of Endogenous Adduct Formation. Cancer Research, 2009, 69, 3052-3059.	0.9	34
21	High mass accuracy assay for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography coupled to orthogonal acceleration time of flight mass spectrometry with multiple reaction monitoring. Analytical and Bioanalytical Chemistry, 2016, 408, 797-804.	3.7	33
22	Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) Tissue by ^{1}Hâ€NMR analysis: evidence for unusual phospholipid metabolism. Prostate, 2008, 68, 1035-1047.	2.3	32
23	Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using labelâ€free quantitative dataâ€independent LCâ€MS. Proteomics, 2014, 14, 4-13.	2.2	30
24	Proteomic diversity of highâ€density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267.	7.1	30
25	Cov-MS: A Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in SARS-CoV-2 Patients. Jacs Au, 2021, 1, 750-765.	7.9	29
26	Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	7.1	28
27	A synthetic approach to the generation of quercetin sulfates and the detection of quercetin 3â€²-O-sulfate as a urinary metabolite in the rat. Bioorganic and Medicinal Chemistry, 2005, 13, 6727-6731.	3.0	27
28	Mutagenicity of DNA adducts derived from ethylene oxide exposure in the pSP189 shuttle vector replicated in human Ad293 cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 678, 129-137.	1.7	26
29	Identification and Characterization of (3â€˜Ââ€˜,4â€˜Ââ€˜-Dihydroxy)-1,N2-benzetheno-2â€˜-deoxyguanosine 3â€˜-Monophosphate, a Novel DNA Adduct Formed by Benzene Metabolites. Chemical Research in Toxicology, 2002, 15, 1088-1095.	3.3	25
30	Simultaneous detection of five different 2â€hydroxyethylâ€DNA adducts formed by ethylene oxide exposure, using a highâ€performance liquid chromatography/electrospray ionisation tandem mass spectrometry assay. Rapid Communications in Mass Spectrometry, 2008, 22, 19-28.	1.5	25
31	Association of gut-related metabolites with outcome in acute heart failure. American Heart Journal, 2021, 234, 71-80.	2.7	25
32	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. Lancet, The, 2015, 385, S26.	13.7	23
33	Qualitative and Quantitative Characterization of Plasma Proteins When Incorporating Traveling Wave Ion Mobility into a Liquid Chromatographyâ€"Mass Spectrometry Workflow for Biomarker Discovery: Use of Product Ion Quantitation As an Alternative Data Analysis Tool for Label Free Quantitation. Analytical Chemistry, 2014, 86, 1972-1979.	6.5	21
34	Ultra highâ€performance liquid chromatography of porphyrins in clinical materials: column and mobile phase selection and optimisation. Biomedical Chromatography, 2012, 26, 714-719.	1.7	19
35	Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach. Lancet, The, 2015, 385, S21.	13.7	19
36	Searching for biomarkers of heart failure in the mass spectra of blood plasma. Proteomics, 2006, 6, 5903-5914.	2.2	18

#	Article	IF	Citations
37	Pro-Substance P for Evaluation of Risk in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 64, 1698-1707.	2.8	17
38	Advances in quadrupole and time‐of‐flight mass spectrometry for peptide MRM based translational research analysis. Proteomics, 2016, 16, 2206-2220.	2.2	16
39	Mass spectrometry in medicine: a technology for the future?. Future Science OA, 2017, 3, FSO213.	1.9	16
40	Travelling wave ion mobility mass spectrometry of 5‐aminolaevulinic acid, porphobilinogen and porphyrins. Rapid Communications in Mass Spectrometry, 2012, 26, 480-486.	1.5	15
41	The uroguanylin system and human disease. Clinical Science, 2012, 123, 659-668.	4.3	13
42	Search for novel circulating cancer chemopreventive biomarkers of dietary rice bran intervention in Apc^{Min} mice model of colorectal carcinogenesis, using proteomic and metabolic profiling strategies. Molecular Nutrition and Food Research, 2015, 59, 1827-1836.	3.3	13
43	Ultra high‐performance liquid chromatography of porphyrins. Biomedical Chromatography, 2012, 26, 331-337.	1.7	12
44	Plasma growth hormone is a strong predictor of risk at 1 year in acute heart failure. European Journal of Heart Failure, 2016, 18, 281-289.	7.1	12
45	Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. Clinical Research in Cardiology, 2019, 108, 940-949.	3.3	12
46	Increased mitochondrial proline metabolism sustains proliferation and survival of colorectal cancer cells. PLoS ONE, 2022, 17, e0262364.	2.5	12
47	Improved analysis of vitamin D metabolites in plasma using liquid chromatography tandem mass spectrometry, and its application to cardiovascular research. Biomedical Chromatography, 2014, 28, 913-917.	1.7	8
48	Mass spectrometric detection of KRAS protein mutations using molecular imprinting. Nanoscale, 2021, 13, 20401-20411.	5.6	8
49	Modulation of acetylcholinesterase activity using molecularly imprinted polymer nanoparticles. Journal of Materials Chemistry B, 2022, 10, 6732-6741.	5.8	7
50	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35.	2.1	6
51	Determination of N7‐glycidamide guanine adducts in human blood DNA following exposure to dietary acrylamide using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2022, 36, e9245.	1.5	6
52	Improving the Diagnostic Accuracy of N-Terminal B-Type Natriuretic Peptide in Human Systolic Heart Failure by Plasma Profiling Using Mass Spectrometry. Journal of Proteome Research, 2007, 6, 3329-3334.	3.7	5
53	Plasma metabolic profiling reveals age-dependency of systemic effects of green tea polyphenols in mice with and without prostate cancer. Molecular BioSystems, 2010, 6, 1911.	2.9	5
54	Porphyrinogen fragmentation profiles by ultra‐high‐performance liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2011, 25, 3749-3757.	1.5	5

#	Article	IF	Citations
55	Tissue distribution and metabolism of the putative cancer chemopreventive agent 3′,4′,5′-trimethoxyflavonol (TMFol) in mice. Biomedical Chromatography, 2012, 26, 1559-1566.	1.7	5
56	Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS). Nucleic Acids Research, 2006, 34, e150-e150.	14.5	4
57	High resolution techniques: general discussion. Faraday Discussions, 2019, 218, 247-267.	3.2	4
58	The measurement of KRAS G12 mutants using multiplexed selected reaction monitoring and ion mobility mass spectrometry. Rapid Communications in Mass Spectrometry, 2020, 34, e8657.	1.5	4
59	Liquid chromatography–tandem mass spectrometry of porphyrins and porphyrinogens in biological materials: separation and identification of interfering poly(ethylene) glycol by travelling wave ion mobility spectrometry/tandem mass spectrometry. Biomedical Chromatography, 2013, 27, 1782-1787.	1.7	3
60	Molecular imprinting as a tool for determining molecular markers: a lung cancer case. RSC Advances, 2022, 12, 17747-17754.	3.6	3
61	Separation and fragmentation study of isocoproporphyrin derivatives by UHPLC-ESI-exact mass MS/MS and identification of a new isocoproporphyrin sulfonic acid metabolite. Journal of Mass Spectrometry, 2014, 49, 80-85.	1.6	2
62	Growth hormone for risk stratification and effects of therapy in acute myocardial infarction. Biomarkers, 2015, 20, 371-375.	1.9	2
63	Data mining and visualisation: general discussion. Faraday Discussions, 2019, 218, 354-371.	3.2	2
64	Novel biomarkers for prediction of poor treatment response in heart failure to guide therapy. Lancet, The, 2014, 383, S32.	13.7	1
65	Dealing with complexity: general discussion. Faraday Discussions, 2019, 218, 138-156.	3.2	1
66	Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω‐3 Fatty Acid and Gemcitabine Administration: A Pilot Study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 738-750.	2.6	1
67	52‐…Discovering New Biomarkers for Predicting Treatment Response in Heart Failure Using Plasma Proteomics. Heart, 2014, 100, A30.1-A30.	2.9	0
68	20‐…Proteomics of human plasma in diastolic heart failure (DHF) using novel chemical affinity, mixed mode matrix (M3). Heart, 2015, 101, A7.1-A7.	2.9	0
69	27‐…High definition lipoproteomics reveal dysregulated redox proteins in coronary artery disease. Heart, 2015, 101, A9.1-A9.	2.9	0
70	The use of turbulent flow chromatography for rapid, on-line analysis of tryptic digests. Rapid Communications in Mass Spectrometry, 2015, 29, 2140-2146.	1.5	0
71	181‐…Enrichment of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), A Novel Pro-Thrombotic Protein in Lipoproteins of South Asian Patients with Coronary Artery Disease. Heart, 2016, 102, A125.2-A125.	2.9	0
72	In Reply. Clinical Chemistry, 2017, 63, 1046-1047.	3.2	0